Is Berkshire Hathaway Being Too Patient With Its Cash?

Berkshire ended 2025 with $373.3B in cash (down from $381.6B at Q3) after spending $9.7B to acquire OxyChem. The firm was a net seller of stocks for the 13th straight quarter (notably trimming Apple and Bank of America) and reported no buybacks in Q4 — its sixth straight quarter without repurchases — though it began repurchasing shares earlier this month. CEO Greg Abel emphasized patience and risk management; the stock's price-to-book has fallen from ~1.8x to ~1.4x, which the article frames as a more attractive valuation backdrop for potential buybacks.

Analysis

Berkshire’s $hundreds-of-billions cash position is not just idle liquidity — it is a latent market-moving bidder that compresses prices for very large, private-market-quality assets. That creates a two-way second-order: sellers face a credible buyer for entire industry roll-ups (chemicals, insurance adjacencies, regional utilities), which lifts private-market valuations and narrows the pool of attractively priced public targets available to other acquirers. Expect deal sizes to skew larger and take longer to clear as counterparties price in Berkshire’s scale and patience.

The steady trimming of concentrated positions (notably large bank and tech stakes) changes market microstructure: incremental selling pressure from a single, very large holder can depress near-term liquidity and create arbitrage opportunities in the most concentrated names. Conversely, Berkshire’s decision framework (no rigid P/B trigger) makes the buyback signal ambiguous; small opportunistic repurchases will be noise until management scales activity meaningfully. This ambiguity raises short-term governance risk (investor impatience or activism) and keeps optionality on the balance sheet expensive in terms of ROE.

From a thematic angle Berkshire’s slow embrace of technology is a structural opportunity cost: absent material stakes in AI/semiconductor infrastructure, the conglomerate cedes asymmetric upside to growthier incumbents even as it preserves downside via cash and insurance float. The most realistic catalysts on the horizon are: (1) a market dislocation within 3–12 months that forces material deployment, (2) a sustained buyback program over 12–24 months that could re-rate the multiple, or (3) activist pressure that accelerates capital returns. Tail risks include mispriced bolt-on deals that dilute long-term returns or inflation/FX erosion of real cash value over multiple years.

Key Decisions for Investors

• Long BRK.B (12-month horizon): buy position size = 1–2% NAV or buy 12–15% OTM call spread to limit premium outlay. Rationale: asymmetric upside if management scales buybacks or executes a few $10–50B acquisitions; downside limited to premium or a ~15% drawdown if cash hoarding continues. Target +20–30% IRR if buybacks/M&A resume; stop/hedge at -12–15%.
• Relative-value pair (3–9 months): long AXP + MCO, short BAC (equal notional). Rationale: favor franchised, fee-like businesses with better secular cash returns vs regional bank cyclicality and ongoing selling pressure. Risk/reward: target 15–25% relative outperformance; tighten or unwind on signs of broader credit stress within 1–2 months.
• Tactical tech exposure (18–36 months): overweight NVDA (LEAPs or concentrated equity) instead of increasing BRK exposure. Rationale: capture missed asymmetric upside from AI infrastructure that Berkshire is unlikely to match quickly. Risk: high volatility; size at 0.5–1% NAV with a 3:1 upside/downside expectation over the multi-year horizon.